Fredun Pharmaceuticals Limited Q2 FY26 earnings call summary

Earnings call of 11 Nov 2025, summarised by AI from the filing.

Fredun Pharmaceuticals Q2 FY26 total income ₹145.29 cr, up 35% year-on-year, with EBITDA ₹22.34 cr and net profit ₹9.73 cr, as it expands pet care through acquisitions.

Key takeaways

1. Q2 results Total income ₹145.29 cr, growing by 35% year-on-year; EBITDA ₹22.34 cr, growing by 60% with margin at 15.37%; net profit ₹9.73 cr, growing by 128%.
2. Acquisitions Acquired One Pet Stop and Wagr.ai, entering organized pet care services and pet tech; acquisition cost zero for Wagr.
3. Pet care driver Pet care is a major driver with Snacky Jain launch, 12 tons sold through preorders, and expansion into 6 major cities.

Original filing on BSE

Fredun Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (13 Aug 2026)
• Q4 FY26: Earnings call (10 Jun 2026)
• Q3 FY26: Earnings call (12 Feb 2026)
• Q2 FY26: Earnings call (11 Nov 2025)
• Q1 FY26: Earnings call (1 Aug 2025)
• Other events: Call transcript (6 Jun 2026), Strategy deck (10 Jun 2025), Strategy deck (10 Jun 2025)